Select Page



Dr. Daniel Stamboulian


Dr. Stamboulian is the founder of the Pan-American Association of Infectious Diseases (API) and other non-profit organizations.

Languages : Spanish, English


Professor Dr. Daniel Stamboulian graduated with honors from the University of Buenos Aires, Argentina, in 1962, and obtained his specialty degree in Pediatrics in 1965. After successfully completing a postdoctoral training in infectious diseases at the University of Southern California, in 1971 he returned to his country. He is the founder of the Pan-American Association of Infectious Diseases (API), where he served as President from 1985 to 1986. Prof. Dr. Stamboulian is also a co-founder of the Argentine Society of Infectious Diseases (SADI), and was the Society’s first President (1983-1986). In 2005, he was named Emeritus Professor of Infectious Diseases at Universidad de Ciencias Empresariales y Sociales (UCES, University of Social and Entrepreneurial Sciences) and in 2008 he was appointed the rank of Voluntary Professor of Medicine at the University of Miami. Since 2010, he holds the title of Honorary Professor at Instituto Universitario CEMIC. Prof. Dr. Daniel Stamboulian is the founder and Chairman of the non-profit organization FUNCEI (Fundación Centro de Estudios Infectológicos) in Argentina. In 2001, he founded FIDEC (Fighting Infectious Diseases in Emerging Countries), a non-profit organization based in the United States. Prof. Dr Stamboulian has received numerous awards throughout his career. In 2010 he was granted the “Bicentennial Medal” (2010), to a prominent member of the Armenian Community in Argentina and in recognition of his work as a medical consultant for the Ministry of Health of the City of Buenos Aires. In 2011, SADI paid tribute to Dr. Stamboulian’s career during its XI Annual Meeting; Asociación Médica Argentina (Argentine Medical Association) and the University of Valparaíso, Chile, awarded him the prize “Professor Carlos Reussi Master of the Andes” and Asociación de Dirigentes de Empresa (Entrepreneur Association) granted him the prize “Entrepreneur 2011 Award, Category Business and Community”. He was also pronounced “Prominent Figure of Science 2011” by the Legislature of the City of Buenos Aires.


Claves para entender al virus del papiloma humano o HPV
El Tribuno

September 08, 2016

Daniel Stamboulian, médico especializado en Infectología y director de Stamboulian Servicios de SALUD, brinda en su sitio digital información importante para conocer sobre el HPV que afecta tanto a hombres como a mujeres. "Dado que la mayoría de las infecciones por HPV no presentan síntomas, muchas personas pueden transmitir el virus sin saberlo", manifiesta el especialista.

Read More

Córdoba: Encuentro con el Dr. Daniel Stamboulian
Diario Armenia

January 01, 1970

El pasado sábado 30 de julio el Dr. Daniel Stamboulian visitó nuestra ciudad para disertar en un congreso de médicos especializados en traumatología, el que tuvo lugar desde el día 29 al 30 de Julio.

Read More


Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers
International Journal of Infectious Diseases

2014This phase III study assessed the safety and immunogenicity of MenACWY-CRM, a quadrivalent meningococcal conjugate vaccine, administered with routine vaccines starting at 2 months of age.

Read Full Article

Risk factors for mortality in burn children
Brazilian Journal of Infectious Diseases

2014Studies about risk factors for mortality in burn children are scarce. We conducted this study to evaluate the risk factors for mortality in pediatric burn patients.

Read Full Article

Immunogenicity, Safety, and Tolerability of Two Trivalent Subunit Inactivated Influenza Vaccines: A Phase III, Observer-Blind, Randomized, Controlled Multicenter Study
Viral Immunology

2012The objective of this study was to evaluate and compare the immunogenicity, safety, and tolerability of two influenza subunit vaccines, a primarily European-marketed trivalent vaccine (Agrippal®, Novartis Vaccines), and a predominantly U.S.-marketed control trivalent vaccine (Fluvirin®, Novartis Vaccines), in subjects aged 3–64 y.

Read Full Article



Area of Expertise

Infectious Diseases

Prevention and Management of Infectious Diseases



Health and Wellness



Share This